The Drug Maker
Knew the Risks.
You Didn't.
If you were prescribed Ozempic, Wegovy, Mounjaro, or another GLP-1 drug and suffered gastroparesis, intestinal obstruction, vision loss, or other serious injury — attorneys handling semaglutide lawsuits and tirzepatide lawsuits may be able to hold the manufacturer liable. Tens of thousands of cases are active. Mass tort litigation is moving. Yours may qualify.
Where the Cases Stand
Where Things
Stand Right Now
GLP-1 drug injury litigation — covering semaglutide lawsuits and tirzepatide lawsuits alike — is one of the fastest-growing mass tort actions in the country. Federal MDL consolidation is active. Bellwether trials are being scheduled. Novo Nordisk and Eli Lilly face mounting evidence that they knew about serious gastrointestinal risks and failed to adequately warn patients and prescribers.
GLP-1 gastroparesis and injury cases are consolidated in federal MDL proceedings. Coordinated discovery is underway and bellwether trial dates are being set — connecting with an attorney now preserves your position.
Tens of thousands of plaintiffs have already filed GLP-1 injury claims against Novo Nordisk and Eli Lilly. Attorneys are actively accepting new semaglutide lawsuit and tirzepatide lawsuit clients as the litigation grows.
Attorneys in this network work on pure contingency. Legal fees come from your settlement or verdict recovery only. If you recover nothing, you pay nothing.
"What drug companies knew — and when they knew it — is the entire case."
Liability Framework
Where Liability
Actually Lives
GLP-1 injury claims — whether styled as an Ozempic lawsuit, a semaglutide lawsuit, or a tirzepatide lawsuit — rest on multiple well-established pharmaceutical liability theories. A connected attorney will identify which apply to your situation and which defendants bear liability.
Failure to Warn
Drug manufacturers have a duty to disclose all known material risks to prescribers and patients. Evidence suggests Novo Nordisk and Eli Lilly were aware of gastroparesis and intestinal risks well before adequate label warnings were issued.
Gastroparesis & Stomach Paralysis
GLP-1 drugs dramatically slow gastric emptying. For many patients, this becomes permanent, debilitating gastroparesis — a condition the manufacturers downplayed in labeling and promotional materials to prescribers.
Intestinal Obstruction & Ileus
Severe GLP-1-induced gut motility suppression can progress to bowel obstruction or ileus requiring emergency surgery. Patients were not adequately warned of this risk prior to or during treatment.
Vision Loss (NAION)
Emerging evidence links semaglutide to non-arteritic anterior ischemic optic neuropathy — a form of sudden vision loss. Studies published in 2024 found substantially elevated risk among GLP-1 users that manufacturers did not disclose.
Pancreatitis & Pancreatic Injury
GLP-1 drugs have been associated with acute and chronic pancreatitis. Failure to adequately warn of pancreatic injury risk — particularly for patients with prior risk factors — forms a distinct liability theory.
Off-Label Prescribing Without Disclosure
Ozempic was approved for type 2 diabetes. Millions received it off-label for weight loss. The manufacturers' aggressive promotion of off-label use without corresponding risk disclosure creates independent liability exposure.
Who Typically Qualifies
Situations That
Typically Qualify
These situations commonly give rise to viable GLP-1 injury claims. An attorney can make the final determination at no cost to you — the evaluation is always free.
You took Ozempic, Wegovy, Mounjaro, or Zepbound
Any GLP-1 or GIP/GLP-1 receptor agonist — semaglutide or tirzepatide — may be covered depending on your injury and timeline.
You were hospitalized for a GI injury
Hospitalization for vomiting, dehydration, gastroparesis, ileus, or bowel obstruction while on or after GLP-1 use is a strong qualifying indicator.
You experienced sudden vision loss
NAION-related vision loss linked to semaglutide use is an emerging, high-value claim category. Even partial vision impairment may qualify.
Risks weren't explained to you
If your prescriber or pharmacist did not specifically warn you about gastroparesis, intestinal obstruction, or vision risks, that failure matters legally.
You have lasting or permanent effects
Ongoing gastroparesis, dietary restrictions, permanent vision impairment, or chronic GI dysfunction significantly increase claim value and eligibility.
Treatment occurred within the past several years
Most states allow claims within 2–3 years of discovery of the harm. The clock may not have started when you first took the drug — only when you linked your injury to it.
Getting Connected
First Call to
Compensation
GLP1Settlements.com connects injured patients with attorneys who handle GLP-1 drug injury cases — including Ozempic lawsuits, semaglutide settlements, and tirzepatide claims — on a contingency basis. Here's what the path typically looks like.
Free Case Review
Submit your information and a licensed attorney will review your situation confidentially. You'll hear back within 48 hours on whether you have a qualifying claim — no commitment required.
Attorney Takes Your Case
If you qualify, the attorney handles everything — medical records, pharmacy documentation, and pharmaceutical liability experts to establish causation and damages on your behalf.
Case Filed in MDL
Your attorney files in the appropriate jurisdiction and enrolls your case in the GLP-1 MDL. Acting now protects your statute of limitations and positions you for early settlement rounds.
Settlement or Verdict
Most pharmaceutical MDL cases resolve in a global settlement. Attorney fees come from your recovery only — you never pay out of pocket regardless of outcome.
Patient Experiences
In Their
Own Words
"I was on Ozempic for eight months. By month six I couldn't keep food down. My gastroenterologist told me I had gastroparesis. Nobody warned me this could happen permanently."
"My doctor prescribed it off-label for weight loss. I ended up in the ER twice with severe vomiting and dehydration. The label said 'nausea.' It didn't say 'stomach paralysis.'"
"I thought the statute of limitations had run. My attorney explained the discovery rule — in my state the clock starts when you connect your injury to the drug, not when you first took it. I still had time."
Answers to What You're Searching
Before You
Call Anyone
Yes. Both Ozempic and Wegovy (semaglutide, manufactured by Novo Nordisk) are named in active pharmaceutical injury litigation. Cases are consolidated in federal MDL proceedings. If you were prescribed either drug and suffered gastroparesis, intestinal obstruction, vision loss, or another serious injury, start your free case review to find out if you qualify.
Mounjaro and Zepbound (tirzepatide, manufactured by Eli Lilly) are included in GLP-1 injury litigation. Attorneys are actively accepting tirzepatide lawsuit clients. While Ozempic and Wegovy semaglutide lawsuits currently represent the largest volume, the liability theory — inadequate risk disclosure — applies equally across the drug class. Get connected with an attorney to assess your tirzepatide claim.
The Ozempic lawsuit — and GLP-1 litigation broadly — centers on gastroparesis (stomach paralysis), intestinal obstruction or ileus, severe vomiting and dehydration requiring hospitalization, acute or chronic pancreatitis, vision loss (NAION), and kidney injury. If your injury required hospitalization or caused lasting harm, submit your information for a free evaluation.
No — and it may actually strengthen it. Ozempic was FDA-approved for type 2 diabetes, but Novo Nordisk aggressively marketed it for weight loss. Prescribing it off-label for weight management without corresponding risk disclosure is a separate, additional liability theory. Millions of off-label Ozempic patients are filing claims. Get a free case evaluation to understand your position.
Possibly not. Most states allow 2–3 years from the date you discovered — or reasonably should have discovered — that your injury was linked to the drug. Many patients are only now making that connection. Contact a GLP-1 attorney today before assuming you're out of time.
No. Pursuing a GLP-1 lawsuit or semaglutide settlement claim does not require discontinuing your medication. Medical decisions remain between you and your physician. Your claim is based on harm already done and the manufacturer's failure to warn — your current prescription status is irrelevant to eligibility. Start your evaluation without changing your treatment.
Settlement values in pharmaceutical MDL cases depend on injury severity, hospitalization history, lost income, permanent impairment, and the strength of your medical documentation. Gastroparesis cases requiring permanent dietary modification or ongoing medical management are consistently among the highest-value claims. The litigation is still early — bellwether trial outcomes will anchor settlement ranges. An attorney can give you a preliminary assessment after reviewing your records.
The Window
Is Still Open.
Drug makers have legal teams working right now. The only thing standing between you and an attorney review is two minutes and a form.